GSK finds a buyer willing to take its Paris R&D site off its hands — for a hefty fee
After shopping the François Hyafil Research Centre near Paris for the past year, GlaxoSmithKline says it finally has a buyer — and the deal will only cost the pharma giant about $40 million.
GSK has pledged the cash to subsidize the employment of 57 staffers at the research facility in Villebon-sur-Yvette over the next four years as part of its agreement to hand it all over to Oncodesign, which evaluates new drug candidates for its customers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
